Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Spruce Biosciences, Inc. Common Stock

SPRB

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.

Last trade $40.44
Day change -$1.81 (-4.28%)
Day range $39.53 – $42.85
Volume 123,339
Market cap $121M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$121.43M
Price / earnings
—
Price / book
1.83×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.67×

Profitability

Earnings per share
-$23.36
Return on assets
-73.03%
Return on equity
-101.29%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.12×
Current ratio
4.83×
Quick ratio
4.83×
Cash ratio
4.69×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$51.21M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SPRB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$697K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$697K
Selling, general and administrative$5.85M$4.35M$4.41M$7M$3.22M$3.12M$3.66M$3.31M
Research and development$18.13M$12.16M$7.58M$4.1M$5.01M-$430K$10.84M$21.46M
Total operating expenses$23.98M$16.51M$11.99M$11.1M$8.23M$2.69M$14.49M$24.77M
Operating income-$23.98M-$16.51M-$11.99M-$11.1M-$8.23M-$2.69M-$14.49M-$24.07M
Interest expense-$1.2M-$1.1M-$674K-$6K-$19K-$29K-$36K-$56K
Income before taxes-$24.01M-$16.23M-$12.27M-$14.65M-$8.21M-$2.07M-$14.04M-$23.56M
Income taxes$0$0$0$0$0$0$0$0
Net income-$24.01M-$16.23M-$12.27M-$14.65M-$8.21M-$2.07M-$14.04M-$23.56M
Net income attributable to common shareholders-$24.01M-$16.23M-$12.27M-$14.65M-$8.21M-$2.07M-$14.04M-$23.56M
EBITDA-$23.24M-$15.88M-$11.74M-$11.1M-$8.23M-$2.69M-$14.49M-$24.07M
Basic earnings per share-$8.51-$6.68-$8.94-$11.04-$14.58-$3.50-$23.95-$42.59
Diluted earnings per share-$8.51-$6.68-$8.94-$11.04-$14.58-$3.50-$23.95-$42.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus

U.S. stock futures rose on Tuesday following Monday's decline, with major indices edging higher. Markets are focused on U.S.-Iran negotiations in Islamabad and Kevin Warsh's Fed Chair confirmation hearing. Key stocks in focus include Apple (CEO transition), UnitedHealth (earnings expected), 3M (earnings expected), Amazon (Anthropic partnership expansion), and Spruce Biosciences (stock offering announcement).

GlobeNewswire Inc.

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.

Zacks Investment Research

Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 7, 20251-for-75reverse split